Maximise the potential of your stem cell applications

Meet Sistemic experts at Stem Cell Meeting on the MESA

29 November: Sistemic, UK: Dr Verna McErlane, Director of Commercial Operations, International at Sistemic, is scheduled to give her own special insight into advanced analytical models to support the stem cell therapy industry at this year’s Stem Cell Meeting on the MESA conference. Participants will have the opportunity to discuss miRNA profiling and learn how to maximise the potential of stem cell applications. The 2011 conference will be held in the Salk Institute for Biological Studies in La Jolla, California on November 30 and December 1. 

Acknowledged experts in cell characterization, Sistemic has recognized a need in the stem cell industry for improved miRNA profiling methodology. The company’s unique approach to miRNA analysis presents significant benefits to stem cell research by providing the tools needed for accurate and rapid cell characterization and an excellent platform for validation prior to commercialization.

Dr Verna McErlane said: “As members of the Alliance for Regenerative Medicine, who are co-organisers of this event, we are particularly delighted to be attending this meeting, which we believe is the premier event for those involved in the stem cell industry.”

 Stem Cell Meeting on the MESA is a two-day conference, which is aimed at bringing together the scientific research and business communities. Dr McErlane will be available throughout the two days to discuss your stem cell analysis objectives and how Sistemic can help you meet those objectives more easily. Sistemic looks forward to meeting you there and supporting the event organizers in their goal to facilitate a bridge between academia and industry and further the translation of clinical research.

For further information come along to the meeting or contact Sistemic directly www.sistemic.co.uk

Cell characterisation experts Sistemic join the Alliance for Regenerative Medicine

08 September 2011: Sistemic, UK: Sistemic Ltd, a fast growing company focused on providing innovative microRNA-based (miRNA) problem-solving services to areas of unmet need within the Cell Therapy/Regenerative Medicine markets and pharmaceutical and biotechnology R&D, is delighted to announce they have joined the Alliance for Regenerative Medicine (ARM). Founded in 2009, the Alliance has more than 80 members, who span research institutes, foundations, companies and investor groups. Their aim is to advance regenerative medicine by representing and supporting members in front of government agencies and the general public.

Sistemic is committed to the regenerative medicine sector and believe ARM has a key role in this exciting area. Support from Sistemic will include access to their cell characterization knowledge, innovative tools and experience for ARM members and also the broader community. Sistemic is confident that their miRNA profiling technology will make a significant contribution to the advancement of cell and regenerative therapies as well as to those developing stem cell lines for drug discovery and development.

Verna McErlane, Director of Commercial Operations, International at Sistemic Ltd, comments: “The revolution promised by cell-based techniques and therapies that regenerate cells, organs and tissues is a key area where Sistemic is making a contribution. Our customers are looking for tools to help them overcome the challenges of commercialisation of cell-based or derived products – namely, the absence of robust and information-rich characterisation and QC methods to monitor cells easily and effectively. Sistemic’s core expertise, the SistemQC^TM product, reduces these hurdles, providing an approach that fits seamlessly within their current workflow.”

SistemQC^TM combines robust miRNA profiling with superior statistical analytics and multi-layered contextual analysis to generate a fingerprint of key miRNAs (kmiRs) providing a succinct read out on the status of the cells, with the added benefit of being able to interpret the underlying biological effects associated with any change observed. These kmiR fingerprints can be adapted to a QPCR method for ease of integration into laboratory routine, and provide rapid testing. The result? Global understanding of cell systems allowing informed decision making for companies, at critical points within their process workflows, allowing them to proceed confidently with their cell populations.

Morrie Ruffin, Managing Director of ARM, said: “We are delighted that Sistemic have joined ARM and look forward to sharing information and understanding as we work together towards advancing the field of regenerative medicine… we feel Sistemic has a great deal to offer the Alliance in helping to support and develop this sector .”

For more information about Sistemic products and services, visit: www.sistemic.com

 End

For press information, please contact:    

Sarah Lawton, Kapler Communications                      

Knowledge Centre, Wyboston Lakes, Great North Road,

Wyboston, Bedfordshire, MK44 3BY, UK

Tel: +44 (0)1480 479280; Fax: +44 (0)1480 470343 sarah@kapleronline.com

 Sistemic UK Ltd.

Thomson Building, Gilmorehill, Glasgow, UK, G12 8QQ

Tel: +44 (0) 141 330 1683 Fax: +44 (0) 141 330 2062 verna.mcerlane@sistemic.co.uk

 Sistemic US Ltd.

28 State Street, Suite 2300, Boston, USA, MA 02109

Tel: +1 (0) 617 523 3272 Fax: +1 (0) 617 725 2897 info@sistemic.co.uk

 Contact:

Dr Verna McErlane, Director of Commercial Operations, International, +44 7855376358

Sistemic shares its views on the cell therapeutics industry

27 July 2011: Sistemic:  Dr Verna McErlane, Director of Operations at Sistemic Ltd., a  leading miRNA-based product company, has recently shared her perspective of the Cell Therapy Industry (CTI) by writing an article for the European Biopharmaceutical Review (EBR), a noted publication supporting the biopharmaceutical industry.

The article reviews the development of CTI up to the current time and examines how the industry can develop to meet the need of untreatable and poorly treated diseases. In addition the article:

• highlights the technology and investment required for CTI to become a major therapeutic industry
• examines current cell characterisation techniques 
• makes a call to action for improved cell characterisation to aid R&D and manufacturing in cell therapeutics
• suggests miRNA profiling as one of the standard methods for cell characterisation

The article is published in the July issue of European Biopharmaceutical Review and will be available on-line at http://www.samedanltd.com/magazine/12

Dr Verna McErlane is Director of Commercial Operations at Sistemic Ltd. and is well known in the cell therapy market. Dr McErlane gained her PhD in cancer drug development and spent time at the Gray Cancer Institute in London  and SPEAR Therapeutics Ltd before moving to the University of Dundee in her native Scotland. Dr McErlane was subsequently asked to take part in the Saltire Foundation Fellowship, a prestigious MBA  Programme, where she spent time working on commercial cell therapy projects with Genzyme and market entry strategies with Axis-Shield. During this time Verna has been able to further her passion for commercialising well founded science into potential therapeutic benefits.  For more information visit: www.sistemic.co.uk

End

For further information please contact:

Dr Verna McErlane, Director of Commercial Operations, International, +44 7855376358